BCRX - BioCryst Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Delayed price. Currency in USD
5.68
+0.01 (+0.18%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous close5.67
Open5.66
Bid5.43 x 500
Ask6.50 x 1000
Day's range5.58 - 5.77
52-week range3.95 - 9.25
Volume759,355
Avg. volume1,081,980
Market cap558.939M
Beta2.38
PE ratio (TTM)N/A
EPS (TTM)-0.65
Earnings date26 Feb 2018 - 2 Mar 2018
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est8.50
Trade prices are not sourced from all markets
  • Globe Newswire14 days ago

    BioCryst Advancing Potential Treatment for Rare and Severely Debilitating Fibrodysplasia Ossificans Progressiva

    BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that it has advanced a program exploring activin receptor-like kinase-2 (ALK2) inhibitors for treatment of Fibrodysplasia Ossificans Progressiva (FOP). Investigational New Drug Application (IND) enabling nonclinical development of optimized lead candidates BCX9250 and BCX9499 has been initiated with the goal of progressing to Phase 1 clinical trials in the first half of 2019. FOP is a very rare disease that affects approximately 1 in 2 million people worldwide.

  • Globe Newswire16 days ago

    BioCryst to Present at the 36th Annual J.P. Morgan Healthcare Conference

    RESEARCH TRIANGLE PARK,  N.C., Jan. 03, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that executives from the Company are scheduled to provide a corporate summary and update regarding the Company’s clinical programs at the 36th annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 10, 2018 at 3:30 p.m. Pacific Time. Links to a live audio webcast and replay of the presentation may be accessed on the BioCryst website events page at http://investor.shareholder.com/biocryst/events.cfm.

  • Here's Why BioCryst Pharmaceuticals Gained as Much as 15.7% Today
    Motley Fool16 days ago

    Here's Why BioCryst Pharmaceuticals Gained as Much as 15.7% Today

    An analyst upgraded the stock to start off the new year.

  • Associated Press2 months ago

    BioCryst reports 3Q loss

    On a per-share basis, the Durham, North Carolina-based company said it had a loss of 18 cents. The results fell short of Wall Street expectations. The average estimate of six analysts surveyed by Zacks ...

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes